Paediatric genomic testing: Navigating medicare rebatable genomic testing

Direct-to-consumer personalized genomic testing.

Over the past 18 months, there have been notable developments in the direct-to-consumer (DTC) genomic testing arena, in particular with regard to issues surrounding governmental regulation in the USA. While commentaries continue to proliferate on this topic, actual empirical research remains relatively scant. In terms of DTC genomic testing for disease susceptibility, most of the research has c...

Consistent Testing for Recurrent Genomic Aberrations

Genomic aberrations, such as somatic copy number alterations, are frequently observed in tumor tissue. Recurrent aberrations, occurring in the same region across multiple subjects, are of interest because they may highlight genes associated with tumor development or progression. A number of tools have been proposed to assess the statistical significance of recurrent DNA copy number aberrations,...

translating hispanic genomic factors in lung cancer into clinical practice: egfr testing for improved outcomes

Means-testing in Medicare.

The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 introduces means-testing of premiums and benefits in two ways. It will means-test the Part B premium, setting higher premiums for better-off seniors. More importantly, it will offer much more generous drug benefits, at low or zero premiums, to lower-income beneficiaries. This paper argues that additional means-test...

Spatially Correlated Mixture Models with Application in Genomic Hypothesis Testing

An important task in genomic studies is the detection of genes satisfying certain conditions, such as being regulatory targets of a transcription factor (TF). With high-throughput data, e.g. microarray data, this is usually formulated as a simultaneous hypothesis testing problem. Gaussian mixture model (GMM) can be used in such a problem. However, standard GMM assumes that all the genes have an...